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Pharmacokinetics and bioavailability of mequindox were determined after single intravenous (i.v.) or 
intramuscular (i.m.) administrations of 7 mg/kg body weight (b.w.) to 10 healthy adult goats. Plasma 
mequindox concentrations were measured by high performance liquid chromatography. 
Pharmacokinetics were best described by a two-compartment open model and an one-compartment 
open model for i.v. and i.m. groups, respectively. The elimination half-life and volume of distribution 
after i.v. and i.m. administrations were statistically different (t1/2, 1.8 to 1.5 h, P < 0.05 and Vd, 0.35 to 
0.45 L·kg-1, P < 0.05, respectively). Mequindox was rapidly (t1/2a, 0.28 h) and almost completely absorbed 
(F, 99.8%) after i.m. administration. In conclusion, 2~3 times daily i.v. and i.m. administration of 
mequindox (7 mg/kg b.w.) in goats may be useful in treatment of infectious diseases caused by 
sensitive pathogens. The plasma disposition kinetics of mequindox in goats is reported for the first 
time. 
 





Mequindox is a broad-spectrum antibiotic derived from 
the family of quinoxaline that also includes olaquindox 
and quinoceton. All three compounds act by inhibiting 
bacterial DNA synthesis. Olaquindox and quinoceton 
have been used to suppress intestinal pathogenic micro-
organisms (such as Escherichia coli) and to promote 
growth of livestock and poultry (Ai et al., 2003; Wan et al., 
2006). The mechanism of growth promotion of these two 
antimicrobials is generally believed to modify and 
promote the intestinal microflora functions (Corpet, 1999; 
Visek, 1978). However, olaquindox has been banned for 
food premix use in poultry in China due to its greater 
toxicity compared with quinoceton, and therefore its use 
has been limited (Wan et al., 2006). Mequindox, with 
chemical name 3-methyl-2-quinoxalinacetyl-1,4-dioxide, 




*Corresponding author. E-mail: zhang.xy@nwsuaf.edu.cn. Tel: 
+ 86 29 8709 1239. Fax: + 86 29 8709 1239.   
 
Abbreviations: i.v., Intravenous; i.m., intramuscular; HPLC, 
high performance liquid chromatography; AIC, Akaike’s 
Information Criterion. 
been mainly used to prevent and treat many intestinal 
infectious diseases in domestic animals, such as 
enteritis, alo laxata and swine dysentery (Yuan, 1998). It 
exhibits excellent broad spectrum antimicrobial activities 
against many kinds of Gram-negative bacteria such as E. 
coli, Papanicolaou bacillus, Salmonella choleraesuis, 
Salmonella typhimurium and Bacillus proteus, and 
against several Gram-positive bacteria such as 
Staphylococcus aureus and 	 (Huang et al., 
2008; Zhao et al., 1982). Furthermore, mequindox has 
advantages including high efficiencies, low toxicities, fast 
absorption, high bioavailability and broad distribution in 
the body (Huang et al., 2008). Especially, it has an excel-
lent activity against Treponema hyodysenteriae (Chen, 
2002; Jia, 1998; Qu et al., 1995). Therefore, mequindox 
has been widely used as both feed additive and paren-
teral solution to prevent and/or treat infectious diseases 
in livestock in China. Little information is available about 
the toxic effects of mequindox despite the fact that high 
doses of mequindox are associated with oxidative stress 
and pathological toxicity in the kidney (Huang et al, 
2010), thus, a long-term large-scale use of mequindox 
can cause great toxicity to domestic animals, and there 
are already many reports about mequindox poisoning in 





Consequently, further research of mequindox is in 
need. Disposition kinetics of both olaquindox and quino-
ceton have been reported in the literature for many 
different animal species involved in swine, piglet, chicken, 
carp etc. (Ai et al., 2003; Zhu et al., 1993; Li et al., 2002, 
2005) while only limited information on the pharmaco-
kinetic behavior of mequindox is acquired. Since the 
pharmacokinetic behavior of antibiotic drugs can be 
influenced by many factors such as formulation, the route 
of administration and animal species (Baggot and 
Mckellar, 1994), the characterization of specific dispo-
sition kinetic varies in different formulations and animal 
species, and is crucial for the appropriate therapeutic use 
of these agents. This study attempted to estimate the 
comparative pharmacokinetics of mequindox in goats 
after i.v. and i.m. administration in order to provide the 








All reagents used during the extraction and analysis were of analy-
tical reagent grade at least. Methanol for preparation of the mobile 
phase was of high-performance liquid chromatographic (HPLC) 
grade (Kermel Chemical Reagent Company, Limited, Tianjin, 
China). Mequindox standards (99.90% purity) and crude mequindox 
(98.90% purity) were provided by the Chinese Veterinarian 
Research Institute Medicine Factory of Chinese Academy of Agri-





Twelve (12) healthy adult goats (6 males) with a mean (± S.D.) 
weight of 30 ± 6 kg were used. The animals were fasted overnight 
(approximately 12 h) before administration, and received only water 
ad libitum. All animals were maintained in accordance with the 
guideline of Regulations for the administration of affairs concerning 
experimental animals (Chinese State Council, 1988). 
 
 
Experimental design  
 
During the experiment, goats were randomly allocated into two 
groups of six animals each. Jugular venous catheters used for 
sampling and infusion were percutaneously placed and secured in 
protective bandages wrapped around the animal’s neck. Catheter 
patency was maintained by daily flushing using a normal saline-
heparin (10 U/ml) solution. Mequindox of a single dosage of 7 
mg/kg b.w. was administered to 2 goat groups by i.v. and i.m., 
respectively. Blood samples (5.0 mL) were collected before admini-
stration (as control samples) and at 5, 10, 15, 30 and 45 min as well 
as at 1, 2, 3, 4, 5, 6 and 7 h after administration from each tested 
animal. All plasma samples were separated by centrifugation and 





Frozen plasma samples were thawed at room temperature and 
then 1.0 ml sample was mixed  with  4.0 l  methanol,  followed   by  




centrifugation (15 min at 12 000 r/min, 4°C). Supernatants were 
filtered by 0.45 ml filter, and then injected into a Beckman HPLC 
system (Los Angeles, USA) for analysis (20 µl for each sample). 
The HPLC was equipped with two 125 Solvent Module pumps, an 
injector with a 20-µl loop, a 166 UV-VIS detector was used for the 
quantification of mequindox. Detection was accomplished by the 
UV absorption at 261 nm. The reverse phase C18 (4.6 × 250 mm, 
5m particle size) column was used. The mobile phase used was 
35% methanol in double-distilled water, and the flow rate was 1.0 






One gram (1 g) mequindox standard was weighed and dissolved in 
1000 ml methanol to give a stock solution of 1 mg/ml. This solution 
was used to prepare standards of 0.5, 1, 2, 4, 8 and 16 g/ml in 0.5 
ml drug-free goat plasma. Standard solutions were extracted and 
analysed in the same way as unknown samples. Calibration curves 
were obtained by plotting the area of mequindox against the cor-
responding concentration of mequindox spiked in goat plasma. The 
HPLC method for mequindox in goat plasma was validated by 
assessing extraction efficiency and inter- and intra- day 





The plasma concentration-time profiles in each individual animal 
were fitted by using residual method (Liu, 2003). The Akaike’s 
Information Criterion (AIC) (Yamaoka et al., 1978) and coefficient of 
variation were used to select the best model to define the plasma 
concentration-time data for each animal. For the estimation of 
pharmacokinetic parameters, the time to reach peak concentration 
(Tmax) and peak concentration (Cmax) were read from the plotted 
concentration-time curve in each individual animal, the area under 
the plasma concentration-time curve (AUC) was calculated by the 
trapezoidal rule with extrapolation to infinity, while volume of distri-
bution (Vd), total body clearance (ClB), distribution and elimination 
half-lives (T1/2ka, T1/2ke) and bioavailability (F) were calculated 
according to standard equations (Gibaldi and Perrier, 1982) . 
Pharmacokinetic parameters were presented as mean ± S.D. and 
were statistically compared by the Student’s t-test. Mean values 
were considered significantly different at P < 0.05. 
 
 
RESULTS AND DISCUSSION 
 
Mequindox was found to be accurately resolved as a 
single sharp peak within 4 minutes and the retention time 
of mequindox were approximately 3.2 min (Figure 1). No 
interference was found from normal endogenous serum 
constituents, which indicated that the chromatographic 
condition was feasible. 
The calibration curve prepared from goat plasma spiked 
with known amounts of drugs was linear between 0.1 and 
16.0 µg/ml mequindox. Correlation coefficients of cali-
bration curves were greater than 0.9995. In goat plasma, 
at three concentrations of 0.5, 1.0 and 5.0 µg/ml, 
analytical recoveries of mequindox were 100.96 ± 0.02, 
95.26 ± 0.12 and 97.98 ± 0.02% (n = 5); intra-day 
coefficients of variation (n = 5) were 3.74, 2.97 and 
3.84%;   inter-day  coefficients  of  variation  (n = 5)  were  










7.98, 4.32 and 7.75%, respectively.  
Plots of the predicted mean concentration vs. time is 
shown in Figure 2. Based on the comparisons of AIC 
values and the range of R2 values in one-, two- and 
three-compartment open model, mequindox concentra-
tion in plasma shows a bi-exponential curve after i.v. 
administration, presenting a phase during which 
concentrations decrease quickly, followed by a slower 
decrease phase, meanwhile, indicating the use of a two-
compartment open model for analysing the data from i.v. 
group. In addition, the disposition of the drug after i.m 
doses can be described adequately by a one-compart-
ment open model. 
The plasma concentrations for i.v. and i.m. routes were 
determined by HPLC (Table 1). The highest initial 
mequindox plasma concentration after i.v. administration 
was detected in the first plasma samples taken 5 min 
post-injection. Table 2 summarizes the mean pharma-
cokinetic parameters for mequindox obtained after i.v. 
and i.m. administration to goats according to the com-
partmental method. After i.v. administration, the initial 
plasma concentration (C0) was 14.65 ± 1.28 g·ml
-1, 
apparent volume of distribution 0.349 ± 0.154 l·kg-1 and 
area under the plasma concentration–time curve from 
zero to infinity (AUC) 34.459 ± 6.244 g·ml-1·h. After i.m. 
administration, maximum plasma concentration (Cmax) 
was 11.01 ± 2.94 g·mL-1 and was reached at 0.667 ± 
0.129h (tmax), terminal half-life (t1/2) was significantly 
shorter in i.m. group (1.494 ± 0.226 h) than for the i.v. 
group (1.784 ± 0.394 h, P < 0.05), the total body 
clearance (CLB/F) after i.m. administration (0.21 ± 0.04 
L·kg-1·h-1) was similar with the group treated with i.v. 
injection (0.209 ± 0.039 L·kg-1·h-1), the apparent volume 
of distribution Vd /F was obtained significantly higher in 
i.m.group (0.452 ± 0.103 L·kg-1) than that in i.v. group 
(0.349 ± 0.154 L·kg-1, P < 0.05). The bioavailability (F) of 
mequindox after i.m. administration was 99.8%. 
To the best of our knowledge, this is the first investi-
gation of the disposition of mequindox in goat after i.v. 
and i.m. administration. Mequindox is best fitted to a two-
compartment open model following i.v. treatment and is 
best described by one-compartment open model following 
i.m. treatment. The drug was found quickly eliminated 
from goat with a terminal t1/2 of 1~2 h after i.v. and i.m. 
administration. Consequently, it should be considered to 
minimize the interval time when mequindox is admini-
stered to goats. The difference in the elimination half-
lives between the two routes (1.78 h with i.v. versus 1.49 
h with i.m.) was statistically different (P < 0.05), which 
may have contributed to a larger Vd value following i.m.. 
In the present study, the absolute bioavailability of i.m. 
mequindox was 99.8%, which indicates that i.m. achieves 
plasma drug concentrations equivalent to or even 
somehow better than i.v.. This is rare, but still could be a 
reasonable phenomenon in pharmacokinetics study. This 
could possibly explained that, in the i.v. administration 
process, the body fluid in the related tissues played a role 
similar to drug absorption enhancer. 






Figure 2. Mean (±S.D.) plasma mequindox concentration in goat following i.v. and i.m. 




Table 1. Mequindox mean concentrations (g/ml) in goat 
plasma after single i.v. and i.m. administration of 7 mg/kg 
b.w. (mean ± S.D., n = 6). 
 
Time (h) i.v. i.m. 
0.083 14.89 ± 2.05 3.12 ± 0.88 
0.167 12.54 ± 0.86 5.49 ± 1.95 
0.25 11.57 ± 0.64 7.56 ± 2.46 
0.5 10.49 ± 0.38 9.83 ± 2.92 
0.75 9.07 ± 0.94 11.09 ± 2.76 
1 8.22 ± 0.53 10.05 ± 2.18 
2 5.46 ± 1.10 7.70 ± 1.60 
3 3.98 ± 0.24 4.80 ± 1.61 
4 2.52 ± 1.05 2.99 ± 1.14 
5 1.76 ± 0.78 1.93 ± 1.21 
6 1.25 ± 0.67 1.12 ± 0.49 
7 0.46 ± 0.37 0.76 ± 0.42 
 




The pharmacokinetics of mequindox have been 
investigated in swine (Chen, 2002) and sheep (Huang et 
al., 2008) in previous studies. It was found that mequin-
dox distributed in swine tissues in 10 min and elimination 
half-life was 2 h  following  i.m.  dosing,  showing  a  more  
Table 2. Pharmacokinetic parameters of Mequindox in goats after 





C0 (g·mL-1) 14.65 ± 1.28 NA 
Cmax (g·mL-1) NA 11.01 ± 2.94 
Tmax (h) NA 0.667 ± 0.129 
t1/2 (h) 0.597 ± 0.825 NA 
t1/2 (h) 1.784 ± 0.394* 1.494 ± 0.226* 
t1/2a (h) NA 0.284 ± 0.196 
Vd /F (L·kg-1) 0.349 ± 0.154* 0.452 ± 0.103* 
CLB/F (L·kg-1·h-1) 0.209 ± 0.039 0.21 ± 0.04 
AUC (g·mL-1·h) 34.459 ± 6.244 34.402 ± 6.862 
F (%) 100 as presuppose 99.8% 
 
C0, Initial serum concentration; Cmax, peak serum concentration; Tmax, 
time to peak serum concentration; t1/2, half-life of distribution; t1/2, half-
life of elimination; t1/2a , half-life of absorption; Vd, the apparent volume of 
distribution; ClB, total body clearance; CLB and Vd represent their true 
values divided by the systemic availability (F); AUC, area under the 
concentration-time curve; F, bioavailability; NA - not applicable. For 





rapid absorption than that of goats, however, not faster 
compared with the terminal t1/2 in goats (1.5 h). 
Mequindox could not be determined in swine serum  after  




8 h post dosing, which is similar to current goat results. 
Compared with values estimated in sheep after i.v., 
mequindox terminal t1/2 in sheep (2.06 h) is longer than 
the value obtained in goats (1.78 h). The clearance of 
mequindox found in the current study in goats (0.209 
L·kg-1·h-1) is similar to the values found in sheep (0.218 
L·kg-1·h-1). The volume of distribution for sheep (0. 643 
L/kg) is much higher than goats (0.349 L/kg), indicating 
that this drug distributed more extensively in sheep.  
The pharmacokinetic behavior and plasma concentra-
tions of mequindox after single i.v. and i.m. administration 
dose of 7 mg/kg b.w. in goats indicate that 2 ~ 3 times 
daily administration could be used for treatment of infec-
tions caused by many susceptible organisms. Moreover, 
the pharmacokinetic parameters of mequindox in goats 
following i.m. administration are characterized by short 
elimination half-life, high bioavailability, and high volume 
of distribution. These results suggest that mequindox 
may be a suitable agent for treatment of infectious disea-
ses in goats. However, further studies are needed to 
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